Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Completed
National Cancer Institute (NCI)
Phase 1
2000-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating
patients who have recurrent primary malignant glioma.
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Completed
Duke University
Phase 1
2000-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating
patients who have recurrent primary malignant glioma.
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Terminated
Center for Cell and Gene Therapy, Baylor College of Medicine
Phase 2
2000-08-01
The major goal of this study is to determine the risks and benefits of bone marrow
transplants in patients with severe thalassemia or sickle cell disease. Participation in this
project will be for two years.
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Terminated
Texas Children's Hospital
Phase 2
2000-08-01
The major goal of this study is to determine the risks and benefits of bone marrow
transplants in patients with severe thalassemia or sickle cell disease. Participation in this
project will be for two years.
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Terminated
The Methodist Hospital Research Institute
Phase 2
2000-08-01
The major goal of this study is to determine the risks and benefits of bone marrow
transplants in patients with severe thalassemia or sickle cell disease. Participation in this
project will be for two years.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
